Back to Search
Start Over
Treatment of Chondroblastoma with Denosumab: A Case Report with a Correlative Analysis of Effect on the RANK Signaling Pathway
- Source :
- JBJS case connector. 11(2)
- Publication Year :
- 2021
-
Abstract
- CASE A 15-year-old boy with chondroblastoma of the right hemipelvis presented with significant periacetabular bone destruction. Neoadjuvant denosumab treatment facilitated initial joint preserving surgery. Unfortunately, he experienced 2 local recurrences and underwent wide surgical resection 2 years after his initial diagnosis. CONCLUSION Inhibition of the receptor activator of NF-κB (RANK)/RANK ligand (RANK-L) pathway with denosumab has been used neoadjuvantly for the treatment of giant cell tumor of bone, but its role in the treatment of chondroblastoma is less understood. This patient's clinical response and effect on cellular RANK/RANK-L activity support the consideration of denosumab in the treatment algorithm for other osteolytic bone tumors such as chondroblastoma.
- Subjects :
- 0301 basic medicine
Oncology
Surgical resection
Male
medicine.medical_specialty
Joint preserving surgery
Adolescent
Chondroblastoma
03 medical and health sciences
0302 clinical medicine
Internal medicine
Medicine
Rank (graph theory)
Humans
Orthopedics and Sports Medicine
Bone Density Conservation Agents
Receptor Activator of Nuclear Factor-kappa B
business.industry
RANK Ligand
medicine.disease
030104 developmental biology
Denosumab
030220 oncology & carcinogenesis
Surgery
Signal transduction
business
Giant-cell tumor of bone
medicine.drug
Signal Transduction
Subjects
Details
- ISSN :
- 21603251
- Volume :
- 11
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- JBJS case connector
- Accession number :
- edsair.doi.dedup.....ec8e95288240b265ffcb6fcb160b4c9c